Wells Fargo Keeps Their Hold Rating on CVS Health (CVS)

In a report released today, Steve Baxter from Wells Fargo maintained a Hold rating on CVS Health (CVS – Research Report), with a price target of $60.00. The company’s shares closed yesterday at $60.26.

Baxter covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Centene, and CVS Health. According to TipRanks, Baxter has an average return of 6.3% and a 56.46% success rate on recommended stocks.

Currently, the analyst consensus on CVS Health is a Moderate Buy with an average price target of $68.53, implying a 13.72% upside from current levels. In a report released on May 29, Robert W. Baird also initiated coverage with a Hold rating on the stock with a $61.00 price target.

The company has a one-year high of $81.71 and a one-year low of $52.77. Currently, CVS Health has an average volume of 12.13M.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CVS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CVS Health (CVS) Company Description:

Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.